
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is a leading global contract research organization with a strong track record of profitability and a solid financial position. Their impressive commercial performance and positive outlook, along with a focus on growing net business wins and profitability, make them a strong long-term investment in the growing biopharma industry. While there may be potential risks in government regulations and stagnant outsourcing, Icon's strong ESG performance and continued growth make it a favorable investment option.
Bears say
Icon is facing headwinds related to higher-than-expected passthrough costs, which are outpacing the initial guidance and creating uncertainty around reported margins. The company's exposure to large pharma clients should insulate it from the recent trend of clinical trial terminations among smaller biotech firms. However, as suspensions and cancellations continue to increase in the early-stage programs, this may impact ICLR's bookings in the future. Additionally, the acquisition of PRA Health Sciences has positioned ICLR as the second-largest clinical stage CRO, which could result in an improvement in operational performance going forward.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares